🚨 How can we safely and effectively deprescribe long-term PPI use?The PEPPER Trial brings new answers and we are excited to share the results with you!The use of proton pump inhibitors (PPIs) has increased substantially, including outside clearly established indications. At the same time, since December 2024, the Belgian National Institute for Health and Disability Insurance (RIZIV/INAMI) has strengthened the monitoring of PPI prescribing, introducing new indicators for the number of patients treated and treatment duration.The PEPPER Trial (Primary carE PPI dEprescRibing trial), supported by KCE Trials, evaluated three strategies for deprescribing long-term PPI use, taking into account the well-known rebound effect.👥 648 patients
👩⚕️ 70 Belgian general practitioners
🔬 3 deprescribing strategies🧪 From research to everyday practiceSymposium highlights:
🔹 Results of 3 deprescribing strategies
🔹 Predictors of successful deprescribing
🔹 GERD & functional dyspepsia
🔹 Clinical & economic impact
🔹 From research to everyday practice
🔹 Panel discussion with Prof. Jan Tack, KCE and PEPPER experts
📍 Liège – 6 October 2026
📍 Leuven – 15 October 2026
🕕 From 18:00👥 For general practitioners
- Limited places👉 Register / information: pepper@kuleuven.be⚠️ In-person events only
Why attend?
Get practical, evidence-based insights to support safe and appropriate PPI deprescribing in your practice.